U.S. Markets closed

VBI Vaccines Inc. (VBIV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7400+0.1000 (+3.79%)
At close: 4:00PM EDT

2.7000 -0.04 (-1.46%)
After hours: 4:57PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.6400
Open2.5300
Bid2.7300 x 21500
Ask2.7400 x 3200
Day's Range2.4500 - 2.7600
52 Week Range0.8700 - 6.9300
Volume3,380,337
Avg. Volume7,201,505
Market Cap696.494M
Beta (5Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Lags Revenue Estimates

    VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -40.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate VBI Vaccines, Inc. (VBIV) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate VBI Vaccines, Inc. (VBIV) to Report a Decline in Earnings: What to Look Out for

    VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
    Benzinga

    Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study

    Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment of chronic HBV infection. The open-label study is designed to evaluate the safety and efficacy of BRII-835 (VIR-2218) compared to the combination of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with and without interferon-alpha as a co-adjuvant. Brii Bio has led the design and implementation of this functional cure proof-of-concept study and is the sponsor of the Phase 2 study. BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. VBI-2601 (BRII-179) is a recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI's prophylactic 3-antigen HBV vaccine candidate and is designed to target enhanced B-cell and T-cell immunity. Price Action: VBIV shares 1.9% at $2.66, while VIR shares are down 1.9% at $47.5 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaTrevena's TRV027 Included In Global COVID-19 StudyHouse Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.